The World's Most Widespread Drug: What Do We Actually Know About Caffeine

A comprehensive scientific overview of caffeine covering its pharmacokinetics, mechanism of action (blockade of adenosine receptors), genetic differences in metabolism (CYP1A2), the dependence potential recognized in DSM-5, paradoxically favorable cardiovascular epidemiological data, and quantified performance benefits in sport (3–6 mg/kg). The article debunks the dehydration myth and explains the history of caffeine's ban and its subsequent removal from WADA's list of prohibited doping substances.

Every day, billions of people swallow it. Sport once banned it; today it tolerates it. Epidemiology says it extends life. Yet most consumers understand it merely as "the thing that wakes me up in the morning." A comprehensive look at a substance everyone knows — and few understand.

Imagine a substance used daily by over 80% of the planet's adult population. A substance that was banned for twenty years at the Olympic Games, but which athletes today legally swallow in tablet form before a race. A substance for which meta-analyses encompassing millions of people consistently find an association with lower mortality — and yet the manual of American psychiatrists classifies it as a source of a withdrawal disorder.

We are talking about caffeine. About 1,3,7-trimethylxanthine, chemically speaking. About a molecule hidden in coffee beans, tea leaves, cocoa beans and guarana. About a substance so ubiquitous that most people do not consider it a drug — even though it meets the pharmacological definition of a psychoactive substance on every point.

And yet, over the past fifteen years, scientific knowledge about caffeine has shifted dramatically. Enormous prospective cohorts following hundreds of thousands of people have produced surprisingly clear results. Meta-analyses of sports studies have quantified performance effects with unprecedented precision. And genetics has revealed why the same espresso energizes one person and leaves another trembling.

This is an attempt to summarize what we actually know about caffeine — without mythology, without marketing, with source data.

The story begins in the stomach and small intestine. Caffeine is absorbed rapidly and almost completely — 99% of an ingested dose is absorbed within 45 minutes. Unlike many other substances, it does not undergo a significant first-pass effect in the liver, so its bioavailability approaches 100%. The highest blood concentration occurs after 15 to 120 minutes, depending on whether you drank an espresso on an empty stomach or a latte after lunch. (Arnaud, 1993; Bonati et al., 1982)

From the blood, caffeine is rapidly distributed throughout the body. It is small enough and fat-soluble enough to cross the blood–brain barrier — the protective rampart between the bloodstream and the brain — without difficulty. In brain tissue it reaches concentrations of around 50 µM, which is a key figure: it roughly corresponds to the value needed to block adenosine receptors. (NCBI Bookshelf, Pharmacology of Caffeine)

And it is precisely the adenosine receptors that are the core of the whole story.

Adenosine is a molecule that gradually accumulates in the brain during wakefulness. It functions as the nervous system's natural brake — by binding to A₁ receptors (distributed throughout the brain) it dampens neuronal activity and the release of excitatory neurotransmitters. A₂A receptors, concentrated in the basal ganglia, in turn functionally block the dopamine pathways responsible for motivation and reward. The result: the longer you are awake, the more adenosine accumulates and the greater the sleepiness you feel. (Fredholm et al., 1999, Pharmacological Reviews; Ferré, 2008, Journal of Neurochemistry)

Caffeine is a competitive antagonist of both types of these receptors. In molecular terms, it "sits down" on the adenosine receptor without activating it — and thereby blocks the site where adenosine would normally bind. The consequence: the brain stops "hearing" the signal to dampen down. The release of noradrenaline, dopamine, acetylcholine and glutamate increases. A person feels alert, focused and motivated.

The essential point is that this is the main and, at ordinary doses, practically the only mechanism of action. Textbooks occasionally mention inhibition of phosphodiesterases or the release of intracellular calcium — but these effects require concentrations of 100–250 µM, that is, several times what you reach even with a fairly strong coffee. With two to three cups a day, it is almost exclusively adenosine blockade. (Ribeiro and Sebastião, 2010, Journal of Alzheimer's Disease)

How long caffeine remains in the body is decided by a single enzyme: CYP1A2. This cytochrome P450 in the liver is responsible for roughly 95% of caffeine's breakdown. The main product is paraxanthine (75–80%), with theobromine and theophylline as secondary products. Less than 3% of caffeine leaves the body unchanged via the kidneys. (Nehlig, 2018, Pharmacological Reviews)

The average half-life — that is, the time over which the plasma concentration drops by half — is about five hours. But "average" is highly misleading here. The actual range is 1.5 to 9.5 hours and depends on a number of factors.

Smokers break down caffeine 30–50% faster, because the polycyclic aromatic hydrocarbons from cigarette smoke increase CYP1A2 activity. Women using hormonal contraception have roughly double the half-life. In the third trimester of pregnancy the half-life lengthens to 15–16 hours, that is, three times normal — and because the fetus has no capacity to break down caffeine, its exposure is prolonged. In newborns the half-life can reach up to 80 hours. (Temple et al., 2017, Frontiers in Psychiatry; Grzegorzewski et al., 2022, Frontiers in Pharmacology)

The greatest source of differences, however, is genetic. The rs762551 polymorphism in the CYP1A2 gene divides the population into two groups. Carriers of the AA genotype — so-called "fast metabolizers" — have high enzymatic activity and process caffeine briskly. Carriers of the AC and CC genotypes are "slow metabolizers" with lower enzyme activity. Among individuals there is a five- to fifteenfold variability in CYP1A2 activity. Roughly half the population falls into the slow-metabolizer category. (Tian et al., 2019, Clinical and Translational Science)

Why does this matter? Cornelis et al. published a study in JAMA in 2006 which showed that consumption of four or more cups of coffee a day increased the risk of non-fatal myocardial infarction exclusively in slow metabolizers (odds ratio 1.64), whereas in fast metabolizers the same dose did not increase risk. (Cornelis et al., 2006, JAMA)

Genetics affects not only the rate of breakdown, but also sensitivity to the effects. The rs5751876 polymorphism in the ADORA2A gene (encoding the A₂A adenosine receptor) influences individual responses to caffeine in terms of both sleep and anxiety. Carriers of one variant are markedly more sensitive to caffeine's effects on sleep than carriers of the other. (Rétey et al., 2007, Clinical Pharmacology & Therapeutics; Childs et al., 2008, Neuropsychopharmacology)

The question of caffeine dependence is often downplayed — "it's not heroin, after all." From a pharmacological standpoint, however, the situation is clear.

Tolerance to some of caffeine's effects develops surprisingly quickly. For the cardiovascular effects (increased heart rate and blood pressure), one to four days of regular use is enough. Tolerance to the performance effects builds more gradually, over the order of two to four weeks. Dependence can form after just three days of regular intake of doses from 100 mg a day — that is, less than one stronger cup of filter coffee. (Watson et al., 2002, British Journal of Clinical Pharmacology)

Caffeine withdrawal syndrome has, since 2013, been an officially recognized diagnosis in the American Diagnostic and Statistical Manual of Mental Disorders (DSM-5, code F15.93). The diagnostic criteria require the onset of at least three of the following symptoms within 24 hours of ceasing consumption: headache, marked fatigue, irritable mood, difficulty concentrating, and flu-like symptoms.

The key review by Juliano and Griffiths from 2004 analyzed 66 studies and mapped the course: symptoms begin 12–24 hours after cessation, peak between the 20th and 51st hour, and last two to nine days. Headache affects roughly half of those abstaining. In 13% of individuals the syndrome reaches such intensity that it clinically significantly impairs everyday functioning. (Juliano and Griffiths, 2004, Psychopharmacology)

Caffeine use disorder is, in the DSM-5, placed in the section requiring further research. According to a study by Sweeney et al. from 2020, 8% of a thousand American caffeine consumers met all three proposed diagnostic criteria. (Sweeney et al., 2020, Journal of Caffeine and Adenosine Research)

Few aspects of caffeine illustrate the gulf between acute and chronic effects as vividly as its relationship to the cardiovascular system.

A single dose of 200–300 mg of caffeine demonstrably raises blood pressure. A meta-analysis by Mesas et al. encompassing randomized controlled trials in hypertensive patients demonstrated an average rise in systolic pressure of 8.1 mmHg and diastolic of 5.7 mmHg. The effect persists for more than three hours. (Mesas et al., 2011, American Journal of Clinical Nutrition)

But long-term studies tell a different story. Ding et al. in 2014 published in the prestigious journal Circulation a meta-analysis of 36 prospective studies encompassing nearly 1.3 million participants. The result: consumption of 3.5 cups of coffee a day was associated with a 15% reduction in the risk of cardiovascular disease (relative risk 0.85). The association had the shape of an inverted letter J — risk fell up to approximately four cups a day and then stabilized. (Ding et al., 2014, Circulation)

Particularly surprising are the data on atrial fibrillation. A meta-analysis by Caldeira et al. from 2013 in nearly 116,000 people found that caffeine does not increase the risk of this arrhythmia — and high-quality studies even showed a 13% reduction. The randomized DECAF trial published by Wong et al. in 2025 in JAMA, in 200 patients with persistent atrial fibrillation, then produced an even more surprising result: coffee consumers had a 39% lower risk of the arrhythmia returning than abstainers. (Caldeira et al., 2013, Heart; Wong et al., 2025, JAMA)

How is this possible? The explanation probably lies in a combination of tolerance to the acute hemodynamic effects (which develops over days), the antioxidant properties of the polyphenols in coffee, and caffeine's anti-inflammatory action on the vascular lining. But honestly: the mechanism is not entirely clarified, and epidemiological data cannot prove a causal relationship — only a statistical association.

Caffeine stimulates the production of gastric acid via bitter receptors on the stomach's parietal cells and accelerates the motility of the large intestine — rectosigmoidal activity increases within four minutes of ingesting coffee. Nevertheless, a meta-analysis by Kim et al. from 2013 found no significant association between coffee and gastroesophageal reflux. (Liszt et al., 2017, PNAS; Kim et al., 2013, Diseases of the Esophagus)

At the hormonal level, caffeine acutely raises levels of cortisol and catecholamines. A study by Lovallo et al. demonstrated a marked rise in cortisol after a 250 mg dose, with the morning response disappearing after five days of regular consumption, but the afternoon increase persisting. Keijzers et al. recorded a fivefold rise in plasma adrenaline. (Lovallo et al., 2005, Psychosomatic Medicine; Keijzers et al., 2002, Diabetes Care)

And then there is dehydration — one of the most tenacious myths about caffeine.

A study by Killer et al. from 2014, with a crossover design in 50 men — regular coffee consumers — tested three-day consumption of four cups of coffee a day (a dose of 4 mg/kg, approximately 308 mg of caffeine) against an equivalent quantity of water. The result: no differences in total body water, urine volume, specific gravity, or osmolality. The authors' conclusion was unequivocal: coffee consumed in moderate amounts by regular consumers has hydrating properties comparable to water. (Killer et al., 2014, PLOS ONE)

Maughan and Griffin, in their review, stated that a profound tolerance develops to caffeine's diuretic effects. A clinically significant diuretic effect occurs only at doses above 500 mg in regular users. (Maughan and Griffin, 2003, Journal of Human Nutrition and Dietetics)

Caffeine appeared on the International Olympic Committee's list of banned substances from 1984. The threshold value was 12 µg/ml in urine. An athlete with a positive test faced disqualification. Under the newly established World Anti-Doping Agency (WADA), caffeine remained banned until 1 January 2004, when it was removed from the list and moved to the Monitoring Program. (Aguilar-Navarro et al., 2019, Nutrients; Diel, 2020, Nutrients)

The reasons for its removal were both pragmatic and scientific.

First, the relationship between the ingested dose and the urine concentration was unreliable — the result depended on body weight, the genetic makeup for breakdown, hydration, and individual consumption patterns. Of more than 11,000 urine samples analyzed by Van Thuyne et al., only 0.1% exceeded the set threshold, which pointed to the ineffectiveness of the regulation.

Second, caffeine is present in coffee, tea, cocoa, cola and energy drinks, and a range of foods. A ban would penalize athletes for normal dietary habits.

Third — and this is crucial from a scientific standpoint — the performance effect manifested even at doses far below the detection threshold. A mere 3 mg/kg of body weight, that is, roughly two cups of coffee, demonstrably improves performance, yet does not reach 12 µg/ml in urine.

Fourth, the health risk at reasonable doses is low compared with genuine doping substances.

Caffeine currently remains in WADA's Monitoring Program. Athletes are not disqualified for it at any concentration. WADA tracks the proportion of samples with a concentration above 6 µg/ml to detect possible patterns of abuse. An analysis of more than 20,000 samples showed that roughly three quarters of elite athletes have detectable caffeine in their urine, with the highest values in cycling, athletics and rowing. (Del Coso et al., 2011; WADA Monitoring Program)

The 2021 position stand of the International Society of Sports Nutrition (ISSN) recommends a performance dose of 3–6 mg/kg of body weight, administered 60 minutes before exertion. For a seventy-kilogram athlete that represents 210–420 mg — that is, roughly two to four strong cups of coffee. The lowest effective dose may be as little as 100–200 mg. Doses above 9 mg/kg increase adverse effects without further performance benefit. (Guest et al., 2021, JISSN)

The main mechanism is not a direct action on the muscles, but a reduction in the subjective perception of exertion in the brain. A meta-analysis by Doherty and Smith demonstrated a 5.6% reduction in perceived effort. (Doherty and Smith, 2005, Scandinavian Journal of Medicine & Science in Sports)

The data from individual sporting disciplines are consistent.

Endurance is the area with the strongest evidence. A meta-analysis by Southward et al. from 2018, encompassing 46 randomized controlled trials, demonstrated an average performance improvement of 3% and a 2.2% reduction in time trial times. A meta-analysis by Wang et al. from 2023 in runners confirmed a significant improvement in time to exhaustion. (Southward et al., 2018, Sports Medicine; Wang et al., 2023, Nutrients)

Muscular strength and power also respond to caffeine, albeit with smaller effects. Grgic et al., in a 2018 meta-analysis, found a significant effect on the one-repetition maximum (mainly for the upper limbs) and on vertical jump height. The largest recorded effects of caffeine in strength training concerned movement velocity — a meta-analysis by Raya-González et al. from 2020 demonstrated a moderate effect on the mean velocity of exercise execution. (Grgic et al., 2018, JISSN; Raya-González et al., 2020, Sports Medicine)

Anaerobic performance (sprints, the Wingate test) also benefits. Grgic, in a 2018 meta-analysis of 246 participants, demonstrated a 3% improvement in mean power and a 4% improvement in peak power. (Grgic, 2018, European Journal of Sport Science)

An umbrella review by Grgic et al. from 2020, synthesizing 21 previous meta-analyses, summed up the situation as follows: caffeine improves performance across all disciplines tested, and the effects are not significantly influenced by sex, age, or type of sport. (Grgic et al., 2020, British Journal of Sports Medicine)

If caffeine is a performance aid for the muscles, it is at least as much one for the brain.

The European Food Safety Authority (EFSA) concluded in 2011 — on the basis of a causal assessment — that 75 mg of caffeine increases both sustained and selective attention. A meta-analysis by Kløve and Petersen from 2025, encompassing 31 randomized controlled trials and 1,455 participants, confirmed this: caffeine acutely improves both reaction time and accuracy in attention tasks. The effect is more pronounced in fatigued and sleep-deprived individuals — Irwin et al., in a 2020 meta-analysis, found a large effect on reaction time and information processing under sleep deprivation. (EFSA, 2011; Kløve and Petersen, 2025, Psychopharmacology; Irwin et al., 2020, Neuroscience & Biobehavioral Reviews)

Interesting are the data from chess. Franke et al. in 2017 conducted a double-blind study on 38 chess players and found that 200 mg of caffeine significantly improved the quality of moves and reduced the number of errors, especially under time pressure — although at the cost of slower decision-making. Caffeine thus aids accuracy, but may slow the pace of play. (Franke et al., 2017, European Neuropsychopharmacology)

A crossover study in elite computer-game players confirmed an improvement in cognitive abilities as well as shooting accuracy after 200 mg of caffeine. (Wu et al., 2024, Scientific Reports)

For long-term memory, a key finding came from a study by Borota et al. from 2014 published in Nature Neuroscience. 200 mg of caffeine administered after learning (not before) significantly improved the discrimination of similar memories after 24 hours. The effect had the shape of an inverted U-curve: 100 mg was not enough, 200 mg was optimal, 300 mg was no better. (Borota et al., 2014, Nature Neuroscience)

Conversely, for working memory the results are ambiguous to negative. Lin et al. in 2023 demonstrated that chronic consumption of 450 mg a day paradoxically worsened working memory — and the deficit persisted even 36 hours after cessation. (Lin et al., 2023, Scientific Reports)

Caffeine has a clear dose-dependency for anxiety-inducing effects. A meta-analysis in Frontiers in Psychology from 2024 demonstrated a large effect of caffeine on increasing anxiety. People with panic disorder are especially sensitive to this effect. (Frontiers in Psychology, 2024)

The impact on sleep is extensive. A meta-analysis by Gardiner et al. from 2023, analyzing 24 studies, quantified the disruption: total sleep time is shortened by 45 minutes, sleep efficiency falls by 7%, sleep-onset latency lengthens by 9 minutes, and deep sleep is shortened by 11 minutes. The authors' recommendation: consume coffee at least 8.8 hours before going to bed. (Gardiner et al., 2023, Sleep Medicine Reviews)

A study in Science Translational Medicine from 2015 further demonstrated that caffeine equivalent to a double espresso consumed three hours before sleep caused a 40-minute delay in the melatonin biorhythm — that is, it shifted the biological clock by almost three quarters of an hour. (Burke et al., 2015, Science Translational Medicine)

The epidemiological evidence on the relationship between coffee and mortality is among the most extensive in all of nutritional science.

Three pivotal studies form the foundation of this knowledge. Freedman et al. in 2012 analyzed more than 400,000 participants in the NIH-AARP study and demonstrated an inverse association of coffee with mortality from cardiovascular disease, respiratory disease, stroke, diabetes and infections. Gunter et al. in 2017, in the European EPIC study with 521,000 participants, found reduced mortality risk among consumers in the highest quartile. And Loftfield et al. in 2018, on data from the UK Biobank with nearly half a million participants, demonstrated an inverse association even among consumers of eight or more cups a day. (Freedman et al., 2012, NEJM; Gunter et al., 2017, Annals of Internal Medicine; Loftfield et al., 2018, JAMA Internal Medicine)

The key meta-analysis by Kim, Je and Giovannucci from 2019, synthesizing 40 studies and 3.85 million people, quantified the optimum: lowest all-cause mortality at 3.5 cups a day (a 15% reduction), lowest cardiovascular mortality at 2.5 cups (a 17% reduction). (Kim, Je and Giovannucci, 2019, European Journal of Epidemiology)

Crippa et al., on a sample of nearly a million participants, calculated the greatest protective effect as a 16% reduction in all-cause mortality at four cups a day. (Crippa et al., 2014, American Journal of Epidemiology)

For Parkinson's disease the data are consistent. A meta-analysis by Santos et al. from 2010 encompassing 26 studies demonstrated a 25% reduction in risk among caffeine consumers, with a clear dose-dependency. Hong, Chan and Bai in 2020 confirmed a roughly 20% reduction in risk and additionally found an association suggesting that caffeine may slow the progression of the disease even in already-diagnosed patients. (Santos et al., 2010, Journal of Alzheimer's Disease; Hong, Chan and Bai, 2020, Nutrients)

For Alzheimer's disease the evidence is promising but less clear-cut. Sezgin et al. found a 32% reduction in risk at one to two cups a day, but at four or more cups the protective effect disappeared. The Finnish CAIDE study demonstrated that 3–5 cups a day in midlife was associated with roughly a 65% reduction in the risk of dementia in later life — but this is a single prospective study with a relatively limited sample, not a meta-analysis. (Sezgin et al., 2023; Eskelinen and Kivipelto, 2010)

In June 2016 the International Agency for Research on Cancer (IARC) reclassified coffee from the group of "possible carcinogens" (2B) to group 3 — "not classifiable as to carcinogenicity." A meta-analysis by Wang et al. analyzing 105 prospective studies demonstrated protective associations with liver cancer (a 54% reduction in risk), endometrial, prostate, colorectal cancer and melanoma. The protective effect for liver cancer is one of the strongest in all of nutritional epidemiology. (Wang et al., 2016, Scientific Reports)

For type 2 diabetes the evidence is exceptionally convincing. Ding et al., on a sample of 1.1 million participants, demonstrated a clear dose-dependency: each daily cup of coffee reduces risk by roughly 6–8%, with six cups a day being associated with a 33% reduction. Interestingly, decaffeinated coffee also shows a protective effect, which suggests a role for polyphenols and chlorogenic acid alongside caffeine itself. (Ding et al., 2014, Diabetes Care; Carlström and Larsson, 2018, Nutrition Reviews)

It would be convenient to tell an unambiguously positive story. But an honest look at the evidence requires several important qualifications.

First, almost all the data on mortality and chronic disease come from observational studies. Association is not the same as causation. It is possible that healthier people simply drink more coffee — the so-called healthy-user bias. Randomized controlled trials lasting decades are, of course, not feasible, so we do not have, and will not have, causal proof in the strict sense.

Second, most studies track coffee consumption, not pure caffeine. Coffee contains hundreds of biologically active substances — polyphenols, diterpenes, melanoidins — and distinguishing the contribution of caffeine from the other components is methodologically difficult. The fact that decaffeinated coffee shows part of the protective effects suggests that caffeine is not the only player.

Third, genetic diversity means that population averages need not hold for a specific individual. For a slow metabolizer with an ADORA2A polymorphism predisposing them to anxiety, the same quantity of coffee that benefits the "average" person may be a source of discomfort or even health risk.

Fourth, caffeine demonstrably has a negative impact on sleep. And sleep is one of the strongest predictors of long-term health. Meta-analyses show a 45-minute reduction in sleep and a reduction in the proportion of deep sleep. It is an open question whether caffeine's protective effects outweigh the harm caused by disrupted sleep — and the answer probably differs from person to person.

The European Food Safety Authority (EFSA) set, in 2015, a safe intake for healthy adults at 400 mg a day and for pregnant women at 200 mg a day. The American FDA and Health Canada agree. For children and adolescents, EFSA proposed a precautionary limit of 3 mg/kg a day.

The lethal dose is estimated at 150–200 mg/kg of body weight, that is, roughly 10–14 grams for an adult — which corresponds to 75–100 cups of coffee drunk at once. Fatal cases have, however, been recorded even at lower doses in susceptible individuals. In practice, overdose poses a threat almost exclusively with pure caffeine powder or highly concentrated tablets — one teaspoon of powder corresponds to roughly 28 cups of coffee.

Caffeine is a contradictory substance. Acutely it raises blood pressure, long-term it protects the heart. Acutely it reduces insulin sensitivity, long-term it reduces diabetes risk. It improves attention, but may worsen working memory. It helps chess players play more accurately, but not faster.

Four insights deserve special attention.

Genetics matters more than most people realize. Half the population are slow metabolizers, for whom four cups a day may carry different risks than for the other half. An approach to recommendations tailored to the individual — ideally underpinned by knowledge of one's own CYP1A2 genotype — makes sense.

Caffeine is the most accessible and most-studied cognitive aid in the world. From chess tournaments through computer games to late-night programming: 75–200 mg improves attention, reaction time and the quality of decision-making with minimal adverse effects. The effect is more pronounced in fatigued individuals. But it need not improve working memory — and with chronic overuse it may even worsen it.

The epidemiological data on the protective effects of moderate coffee consumption are remarkably consistent. Across millions of people followed, dozens of studies and different continents, the same pattern recurs: 3–5 cups a day is associated with a 13–17% reduction in all-cause mortality and a significant reduction in the risk of Parkinson's disease, type 2 diabetes and liver cancer. But these are statistical associations, not proven causation — and they do not necessarily hold for every individual.

And finally: caffeine is a legitimate performance aid. Its removal from the list of banned substances in 2004 was both pragmatically and scientifically justified. At doses of 3–6 mg/kg it improves performance by 2–6% across sporting disciplines. But doses above 9 mg/kg bring no further benefit — only adverse effects.

The world's most widespread drug deserves more than oversimplification. Neither uncritical optimism nor needless fear. It deserves precise data. And there is, as it turns out, more than enough of that available.

The article is based on meta-analyses and systematic reviews published in peer-reviewed scientific journals. Key sources: Kim, Je and Giovannucci (2019, European Journal of Epidemiology), Guest et al. (2021, JISSN), Ding et al. (2014, Circulation and Diabetes Care), Nehlig (2018, Pharmacological Reviews), Grgic et al. (2020, British Journal of Sports Medicine), Gardiner et al. (2023, Sleep Medicine Reviews), Juliano and Griffiths (2004, Psychopharmacology). A complete list of sources is available in the underlying research material.

Transparency of creation

The conception, structure and editorial line of the article are the work of the author, who prepared the content outline, established the key theses, and directed the entire creative process. Generative AI (Claude Opus 4.6, Anthropic) was used as a tool for research, fact-checking, and fleshing out the author's draft.

The author verified the key findings and approved the final wording. No part of the text was published without conscious authorial control. The factual data were verified against the publicly available sources cited in the text.

The procedure complies with the transparency principles of EU Regulation 2024/1689 (AI Act). #poweredByAI